         
|
|
|
|
1st appeared
13 October
1999 Osteoporosis Drug Rapidly Reduces Risk of Bone Fractures Based on recent findings from the largest osteoporosis study to date, researchers at UC San Francisco are calling an investigational drug for postmenopausal women an excellent new weapon in the fight against osteoporosis. In a placebo-controlled study of 2,458 post-menopausal women with osteoporosis, researchers found that after three years of treatment with the drug, called risedronate, the incidence of new fractures of the spine (vertebral) was reduced by 41 percent and non-vertebral fractures by 39 percent among women taking risedronate compared to those receiving a placebo. As a further indication of the drug’s effectiveness, after just one year of treatment with risedronate, the incidence of new spinal fractures was reduced by 65 percent among women in the risedronate group compared to those in the placebo group. The study is published in the October 13 issue of the Journal of American Medical Association. "Risedronate has also been shown to increase bone mass, stop bone loss, and produce healthy bones in women with established postmenopausal osteoporosis," said Steven T. Harris, chief of the Osteoporosis Clinic at UC San Francisco and lead author of the study. Links: Journal of American Medical Association Related stories: Study Results Suggest First Potential Osteoporosis Cure Book by UCSF Professor Details the Prevention and Treatment of Osteoporosis Study Shows Drug Reduces Risk of Spine and Hip Fractures in Women with Osteoporosis Source: Abby Sinnott, News Services |
||
|
DAYBREAK | ARCHIVES | CALENDAR
| CAMPUS NOTES Copyright ©1999 Regents
of the University of California. All rights reserved. |
||
